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ABSTRACT 
Over the past decade or more, the prevalence of traditional risk factors for cardiovascular diseases has been increasing in the major 
populous countries of the developing world, including India, with consequent increases in the rates of coronary and cerebrovascular 
events. Cardiovascular diseases are predicted to be the major causes of morbidity and mortality in most developing nations around 
the world. Historically, most populations from South Asia have documented low levels of CV risk factors, particularly blood lipid 
levels, diabetes, and hypertension. However, in recent decades, the prevalence of these risk factors has increased, especially in urban 
areas. Numerous differences exist between younger and older women and between women and men with respect to the pathology of 
CHD and its incidence and prevalence over the life cycle. Women with obesity, metabolic syndrome, or diabetes have lipid proﬁles 
that adversely affect CHD risk.  
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INTRODUCTION: 
Despite an overall reduction in the death rate due to 
cardiovascular disease (CVD) in the United States over 
the last several decades, the rate of decline is less for 
women than men and less for African-American women 
than white women.
1
Due to an aging population, the 
absolute number of deaths due to CVD in women is 
actually increasing. Because the risk of CVD increases 
with age, there is a need for an increased awareness of 
the importance of CVD as a major public health issue 
for older women.  
CVD, particularly coronary heart disease (CHD) and 
stroke, remains the leading killer of women in most 
developed countries.  CVD is a particularly important 
problem among minority women. This article discusses 
recent advances in knowledge of the occurrence, 
determinants, and treatment of atherosclerotic CVD in 
women, including CHD, hypertension, stroke, and 
peripheral arterial disease and much attention has been 
directed toward a better appreciation of the influence of 
gender on cardiovascular risk and management, but 
important gaps in knowledge remain. Recent 
developments in cardiovascular research undoubtedly 
will have a significant impact on prevention, clinical 
care, and outcomes of women and will provide direction 
for future work.
2
 
Secondary Prevalence of CVD: 
Secondary prevention of CVD refers to healthcare that 
aims to prevent the recurrence of cardiovascular events 
(e.g. heart attack or stroke) or complications of CVD in 
people diagnosed with CVD
3
. 
Secondary prevention strategies for CVD are 
modification of behavioral risk factors, psychological 
care, and adherence to prescribed medicines, education 
and support for self-management, medical care, cardiac 
rehabilitation services, and multidisciplinary CHF 
management services
.
 
The prevalence of different “lifestyle” and biological 
CVD risk factors across the country – and results show 
that these risk factors are now at higher levels in India 
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than in developed countries and regions such as the 
USA and Western Europe
4
. 
The prevalence of coronary heart disease (CHD) is 
known to be very high among Indians, both in India and 
abroad. Moreover, among Indians, CHD occurs at least 
a decade or 2 earlier compared with Europeans. The 
reason for the increased susceptibility of Indians to 
CHD is yet to be completely understood. However, 
several studies have hinted that the clustering of risk 
variables (mechanism of which is still unknown) of 
metabolic syndrome (MS) could be responsible for the 
increasing incidence of CHD among Indians. This 
includes central obesity, hypertriglyceridemia, less 
levels of high-density lipoprotein cholesterol, high blood 
pressure, and high levels of fasting blood glucose. 
Secondary prevention relies on early detection of 
disease process and application of interventions to 
prevent progression of disease.
4
 
There is a significantly lower age-specific risk of CHD 
in women than men. Risk of death due to CHD in 
women is roughly similar to that of men 10 years 
younger. Despite their marked advantage in age-specific 
risk of CHD death, the greater likelihood of survival of 
women to advanced ages produces nearly equal numbers 
of actual deaths due to CHD in men and women.  
Treatment efforts in women may be less likely to be 
effective in reducing the death rate because the majority 
of cases may never reach a hospital. For these women, 
primary prevention is likely to be the only practical 
solution. Prevalence of ECG-defined MI shows similar 
trends with comparable rates among women in the two 
ethnic groups but higher rates in non-Hispanic white 
men compared with Hispanic men. More recent data 
from the Corpus Christi Heart Project demonstrate 
higher hospitalization rates for heart attacks and incident 
MI in Mexican-Americans compared with non-Hispanic 
whites for both men and women. This same study 
demonstrated a higher case-fatality after MI in Mexican-
Americans and women compared with non-Hispanic 
whites and men, respectively.
 
WOMEN SPECIFIC VARIABLES: 
 Preeclampsia: 
The association between preeclampsia and 
cardiovascular disease has been an increasing area of 
interest over the last years. Cardiovascular disease is the 
number one cause of death in women in the western 
world and more women than men die of heart disease 
each year. The most common pregnancy disorder is 
preeclampsia. Preeclampsia is defined by hypertension 
and de novo proteinuria and remains responsible for 
high maternal and fetal morbidity and mortality 
worldwide. Pregnancy has been described as a "stress 
test" for future cardiovascular disease, to identify 
women young enough to benefit from screening. 
Women with a history of early onset (severe) 
preeclampsia have the highest risk of cardiovascular 
disease later. However, the exact underlying link 
between the two disorders is still unknown. In this 
review we describe different facets of the association 
between preeclampsia and cardiovascular disease and 
we give an overview of the recent literature
4
. 
 Gestational diabetes: 
Gestational diabetes, which develops only during 
pregnancy and usually disappears after the pregnancy, 
increases the risk that the mother will develop diabetes 
later. The condition is managed with meal planning, 
activity and sometimes insulin or other medications. 
Pregnant women who develop gestational diabetes may 
be more at risk of developing heart disease later in life, 
according to new research
5
.  
Gestational diabetes only occurs during pregnancy. It 
happens when hormones activated during pregnancy 
weaken the effect of insulin, the hormone that normally 
allows cells to absorb glucose from the blood.  
Factors that can make pregnant women at greater risk of 
getting gestational diabetes include having a family 
history of diabetes, having previously had an 
unexplained miscarriage, being older than 25 when they 
became pregnant or being overweight before becoming 
pregnant.  
Women who develop gestational diabetes are usually 
able to control their blood sugar without harming their 
baby's health. But having gestational diabetes does make 
women more likely to develop diabetes 5-10 years after 
giving birth.  
The new study finds that women who get gestational 
diabetes while pregnant also have an associated risk of 
atherosclerosis - where the arteries around the heart 
become clogged by fatty substances. Because 
atherosclerosis disrupts the flow of blood to and from 
the heart, this can eventually cause heart attacks and 
other cardiovascular diseases
6
. 
Autoimmune disease: 
Autoimmune diseases (AIDs) have been associated with 
accelerated atherosclerosis (AT) leading to increased 
cardio- and cerebrovascular disease risk. Traditional risk 
factors, as well as systemic inflammation mediators, 
including cytokines, chemokines, proteases, 
autoantibodies, adhesion receptors, and others, have 
been implicated in the development of these vascular 
pathologies. Yet, the characteristics of vasculopathies 
may significantly differ depending on the underlying 
disease. In recent years, many new genes and signalling 
pathways involved in autoimmunity with often 
overlapping patterns between different disease entities 
have been further detected. Epigenetics, the control of 
gene packaging and expression independent of 
alterations in the DNA sequence, is providing new 
directions linking genetics and environmental factors. 
Epigenetic regulatory mechanisms comprise DNA 
methylation, histone modifications, and microRNA 
activity, all of which act upon gene and protein 
expression levels. Recent findings have contributed to 
our understanding of how epigenetic modifications 
could influence AID development, not only showing 
differences between AID patients and healthy controls, 
but also showing how one disease differs from another 
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and even how the expression of key proteins involved in 
the development of each disease is regulated
7
. 
Thyroid diseases: 
Common cardiovascular symptoms associated with 
thyroid conditions include a rapid heart rate, angina 
pectoris, atrial fibrillation, and congestive heart failure. 
Cardiac symptoms can be seen in anybody with 
hypothyroidism but are especially likely in an individual 
who already has underlying heart disease (Figure). 
Subclinical hyperthyroidism is associated with 
important cardiovascular risk factors, yet there are 
conflicting results on cardiovascular mortality
8
. 
Rheumatoid arthritis: 
The increased mortality in rheumatoid arthritis (RA) is 
mainly due to (atherosclerotic) cardiovascular disease. 
The cardiovascular morbidity is also increased in 
comparison with the general population. This increased 
cardiovascular burden could be caused by 1) an 
enhanced prevalence of cardiovascular risk factors 2) 
under treatment of cardiovascular risk factors or 3) RA 
itself, particularly due to its chronic inflammatory 
component. Cardiovascular risk factors only partially 
explain the increased cardiovascular risk and it is 
becoming increasingly acknowledged that the 
underlying inflammation in RA plays an essential role. 
This is probably related to the fact that atherosclerosis 
also has an inflammatory etiology that is accelerated by 
RA. Similarly, it can be expected that effective 
suppression of this inflammatory process by disease 
modifying antirheumatic drugs and/or biologicals lowers 
the cardiovascular risk. Altogether, there is 
accumulating evidence that the increased cardiovascular 
risk in RA is comparable to that of type 2 diabetes and 
actually RA should be seen as a new, independent, 
cardiovascular risk factor for which cardiovascular risk 
management is essential
9
. 
Gout: 
Gout is known to boost the risk of a heart attack in men. 
But to date, little has been known about the impact of 
gout on women's cardiovascular health. 
Gout is common and caused by inflammation in the 
joints as a result of excess uric acid deposits. Uric acid 
is a by-product of purines, which are abundant in a 
Western diet. 
Obesity, weight gain, high alcohol intake, high blood 
pressure, poorly functioning kidneys and certain drugs 
can all precipitate its development. 
Compared with women who did not have gout, those 
who did were 39% more likely to have a heart attack of 
any kind and 41% more likely to have a non-fatal heart 
attack. 
The risks were significantly higher among the women 
than among the men. Men with gout were only 11% 
more likely than those without the disease to have a fatal 
or non-fatal heart attack. 
The findings held true after adjusting for factors likely 
to influence the results, such as age, other underlying 
health problems, and use of prescription drugs
10
. 
The authors comment that excess uric acid may boost 
levels of inflammation and platelet stickiness, both of 
which are implicated in coronary artery heart disease. 
Other forms of arthritis also boost the risk of 
cardiovascular disease
10
. 
Hormone therapy: 
The net benefit of estrogen or combined estrogen-
progestin replacement therapy in postmenopausal 
women is still uncertain. Based upon extensive 
observational data, it was believed that estrogen was 
cardioprotective; as a result, estrogen therapy was 
routinely prescribed for both primary and secondary 
prevention of coronary heart disease (CHD) 
11
. 
Normal women have menopause at a mean age of 51 
years, with 95 percent becoming menopausal between 
the ages of 45 to 55 years. Estrogen is the most effective 
treatment available for relief of menopausal symptoms, 
most importantly, hot flashes. Postmenopausal hormone 
therapy (estrogen alone or combined with a progestin) is 
currently indicated for management of menopausal 
symptoms
12
. 
Psoriasis: 
There is considerable evidence to show that patients 
with moderate-to-severe psoriasis have a significantly 
increased risk of cardiovascular disease and 
cardiovascular risk factors such as obesity, diabetes 
mellitus, the metabolic syndrome and smoking 
compared to the general population. The mechanistic 
link between psoriasis and this observed increase in 
cardiovascular co-morbidities has not been fully 
defined. It is clear, however, that common inflammatory 
pathways are at play in the pathophysiology of psoriasis, 
obesity and coronary artery disease. It had been 
proposed that the control of systemic inflammation in 
psoriasis could help reduce cardiovascular morbidity, 
and retrospective studies of methotrexate and anti-TNF-
a agents have suggested a cardio-protective effect with 
use of these agents. More recently, however, there have 
been concerns regarding a potential excess of 
cardiovascular events with the newer generation of anti-
interleukin-12p40 antibodies. In this article we review 
the association of psoriasis with cardiovascular 
disorders and the effects of current psoriasis therapies 
on cardiovascular risk
13
. 
Pregnancy induced hypertension: 
Women with a history of pregnancy-induced 
hypertension (including preeclampsia) are at increased 
risk of cardiovascular and metabolic diseases later in 
life. However, it is not known whether the increased risk 
can be attributed to factors that originate in pregnancy or 
to prepregnancy factors that are associated with both the 
risk of preeclampsia and gestational hypertension and 
the subsequent risk of cardiovascular and metabolic 
diseases
14
. 
Risk Factors and Primary Prevention 
The major risk factors for CHD in women are cigarette 
smoking, hypertension (including isolated systolic 
hypertension), dyslipidemia, diabetes mellitus, obesity, 
sedentary lifestyle, and poor nutrition. Although most 
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risk factors for CHD are similar in men and women, 
gender differences have been documented, particularly 
diabetes and dyslipidemia. The prevalence, magnitude 
of effect, and gender differences in identified risk 
factors for CHD are summarized below.  
Cigarette smoking remains the leading preventable 
cause of CHD in women, with more than 50% of MIs 
among middle-aged women attributable to tobacco.
16
 
Risk of CHD begins to decline within months of 
smoking cessation and reaches the level of persons who 
have never smoked within 3 to 5 years. Smoking 
cessation rates have declined more slowly among 
women than men. On the basis of current trends, it is 
estimated that smoking rates will be higher in women 
than in men. These changing demographics of smoking, 
particularly the unfavorable smoking patterns among 
younger women, may contribute substantially to the 
future burden of CHD on women, as well as other 
smoking-related illnesses.  
Epidemiological studies document a strong association 
between high levels of both systolic and diastolic blood 
pressure (BP) and risk of CHD in both women and men. 
Among adults older than 45 years, having hypertension 
(defined as either taking antihypertensive medication or 
having systolic BP≥140 mm Hg or diastolic BP >90 mm 
Hg). approximately one half of identified hypertensive 
subjects were receiving treatment with antihypertensive 
medication, but only about some had hypertension that 
was well controlled (BP <140/90). Of particular concern 
for older women is isolated systolic hypertension, which 
is estimated to affect some of women older than 65.  For 
severe diastolic hypertension (diastolic BP ≥110), the 
benefits of medication are large and obvious for both 
sexes. Primarily β-blockers and thiazide diuretics were 
used, shows a significant effect for stroke and major 
CVD events in women. The relative risk reduction did 
not differ between men and women. Weight reduction 
and dietary interventions also have important roles in 
prevention and treatment of hypertension.
17
  
Increased total serum cholesterol and low-density 
lipoprotein (LDL) cholesterol are risk factors for CHD 
in both women and men. From 1980 to 1991 more than 
50% of women older than 55 years had serum 
cholesterol levels that were considered high (>240 
mg/dL). A low level of high-density lipoprotein (HDL) 
cholesterol, however, was a risk factor for CHD in both 
younger and older women and was a stronger predictor 
of CHD mortality in women than in men. The role of 
triglycerides in CHD risk remains controversial, but 
observational studies suggest they may be a particularly 
important risk factor in women and the elderly, the 
majority of whom are women.
18
  
Obesity and sedentary lifestyle are parallel, interrelated 
epidemics that contribute to increased risk of CHD. The 
prevalence of obesity has increased among both men 
and women in the past decade; currently about one third 
of adult women are classified as obese. Moreover, 60% 
of both men and women have no regular physical 
activity. Obesity, particularly abdominal adiposity, is an 
important risk factor for CHD in women. Although most 
of the epidemiological studies of exercise and CHD 
have been conducted in men, most studies in women 
suggest a comparable 50% risk reduction among active 
women compared with sedentary women. Recent 
evidence suggests that even moderate-intensity activity, 
including brisk walking, is associated with substantial 
reduction in CHD risk.
19
 
Regular exercise and maintenance of healthy weight 
should also help reduce insulin resistance and the risk of 
non–insulin-dependent diabetes mellitus, which appears 
to be an even stronger risk factor for CHD in women 
than in men. Diabetes is associated with a threefold to 
sevenfold elevation in CHD risk among women, 
compared with a twofold to threefold elevation among 
men; this gender-based difference may be due to a 
particularly deleterious effect of diabetes on lipids and 
blood pressure in women. Diabetes is the fourth leading 
cause of death among black women and third among 
Hispanic women aged 45 to 74 years and American-
Indian women aged 65 to 74 years. It is also the second 
leading cause of death in Pima Indian women. 
Approximately half of all deaths in persons with non–
insulin dependent diabetes mellitus are due to heart 
disease, the majority of which is ischemic heart 
disease.
20
  
Increasing research and knowledge related to nutrition 
have led to identification of several dietary factors that 
influence CHD risk. The epidemiological evidence is 
compelling: diets low in saturated fat and high in fruits, 
vegetables, whole grains, and fiber are associated with a 
reduced risk of CHD. Trans fatty acids have recently 
been linked to adverse lipid profiles and an increased 
risk of CHD. The role of other fatty acids, including 
monounsaturated, polyunsaturated, and marine omega-3 
fatty acids, remains controversial. Moderate intake of 
alcohol is related to reduction of CHD but may raise 
blood pressure and increase risk of breast cancer. 
21
 
Genetic factors are also important determinants of CHD 
risk in both men and women, but they are not modifiable 
and thus are not further addressed here. Recently 
identified thrombotic, hemostatic, and inflammatory 
markers for CHD have promising roles in predicting risk 
of vascular events, but their clinical usefulness in the 
general population remains largely unknown.  
Pharmacological interventions, including antiplatelet 
therapy and postmenopausal hormone replacement 
therapy, are appropriate in selected patients. In primary 
prevention the balance of benefits and risks of aspirin 
prophylaxis among women remains unknown and 
awaits the results of the ongoing Women’s Health 
Study, the only randomized trial of aspirin in usual-risk 
women. Antioxidant vitamin supplements, particularly 
vitamin E and homocysteine-lowering agents such as 
folate and B6, have promising roles in prevention of 
CHD, but conclusive evidence awaits the results of 
several ongoing randomized clinical trials.
32
 Early 
surgical menopause is linked to increased risk of CHD, 
which appears to be negated by the use of estrogen 
therapy.
22
 
Cardiac Rehabilitation 
A recent secondary prevention consensus panel of the 
AHA found compelling scientific evidence that 
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comprehensive risk factor interventions in patients with 
CHD extend overall survival, improve quality of life, 
decrease the need for interventional procedures, and 
reduce the incidence of subsequent MI. Cardiac 
rehabilitation is a key step initiating the process of risk 
reduction and restoration of functional capacity after a 
heart attack or revascularization. It is an established 
treatment that includes exercise training, risk factor 
modification, and psychosocial and vocational 
counseling. Studies that have included women suggest 
they have similar improvements in functional capacity 
and other outcomes compared with men.
23
 
Stroke 
Epidemiology 
Stroke represents a significant healthcare burden for our 
society. It is the third leading cause of death in the 
United States and the leading cause of disability, with an 
estimated direct cost of $41 billion per year. Healthcare 
costs increase dramatically as stroke severity increases, 
with greatest costs occurring for those patients with 
subarachnoid hemorrhages, the only subtype of stroke 
more common in women than in men.Strokes account 
for half of acute neurological hospitalizations. Stroke 
survivors are at greater risk of dementia and disability 
than men and women without a history of stroke.
24
 
The overall prevalence of stroke is higher in men than in 
women but increases with age in both gender groups. 
However, the incidence of ischemic stroke for persons 
with a history of transient ischemic attacks (TIA) is 
higher in women than in men. Seasonal effects on the 
incidence of stroke in men and women have been 
suggested but not confirmed by all studied.
25
  
Although the lifetime risk of stroke is higher in men, 
women are more likely to die of stroke, probably due to 
their older age at its occurrence and their longer life 
expectancy. Over an entire lifetime, about 16% of 
women will die of stroke, whereas only 8% of men will 
die of stroke. However, mortality rates over the last 
decades have been declining for both men and women
25
.  
Risk Factors 
Many identifiable risk factors for ischemic stroke in 
both men and women have been fairly consistent over 
epidemiological studies. They include hypertension, 
smoking, diabetes mellitus, ischemic heart disease, atrial 
fibrillation, and TIAs. Most epidemiological studies 
have not provided gender-specific relative risks  
Hypertension is clearly a major risk factor for stroke, 
with a 46% increase in stroke risk for every 7.5 mm Hg 
increase in diastolic blood pressure. In black women the 
risk of developing hypertension is more than twice that 
of white women. Current smoking habits are related to 
stroke risk for both men and women even after 
adjustment for age, gender, and hypertension
26
. 
Diabetes mellitus is associated with a doubling of 
ischemic stroke risk.
 
Not only does diabetes increase 
stroke risk, it increases severity and mortality associated 
with stroke
27
. 
Treatment 
To date there are no specific recommendations for 
treatment of stroke in women, and recommendations for 
acute interventions for women and men appear to be the 
same. For all stroke victims, early detection and 
treatment are vital. Thrombolytic therapy with r-TPA 
for acute ischemic stroke can be effective for ischemic 
stroke patients when administered early in the course of 
the event. Recently, a panel of the American Heart 
Association Stroke Council reviewed the clinical trials 
of thrombolytic drugs and established guidelines for 
management of patients with acute ischemic stroke. The 
guidelines call for early administration of r-TPA when 
the time of stroke onset can be ascertained reliably and 
with some specific exclusions. Ten percent of patients 
with acute stroke develop hemorrhage with r-TPA. The 
panel also considered the need for careful attention to 
ancillary care measures and management of bleeding 
complications, and these are outlined in the guidelines. 
Although treatment after the acute stage should focus on 
the patient’s particular risk factor profile and the 
pathogenesis of the stroke, most care will include the 
use of antiplatelet aggregating or antithrombotic agents 
such as aspirin, ticlopidine, or warfarin. Secondary 
prevention may include aspirin for both men and 
women. While women and men both received equal 
benefit with aspirin therapy in this trial of secondary 
prevention, the efficacy of aspirin use for primary stroke 
prevention in women remains questionable. In patients 
with TIA and atrial fibrillation, adjusted dose warfarin 
may prevent stroke.
28
  
Peripheral Artery Disease 
Epidemiology 
Peripheral artery disease is more prevalent in women 
than generally appreciated, but estimates vary greatly 
according to the diagnostic criteria applied. Prevalence 
and incidence rates do not differ significantly by gender, 
although incidence rates in women lag behind those in 
men in a pattern similar to that for coronary disease. The 
incidence of peripheral artery disease increases sharply 
with age regardless of the criteria applied. In the 
Framingham study, age-specific incidence accelerated 
rapidly in women. Intermittent claudication is not a very 
sensitive indicator of disease; when used as the sole 
criterion, it yields prevalence rates of just 2% to 3%. 
Absence of pulses is also not a sensitive indicator.
29
 
Data from a variety of studies clearly show that the risk 
of cardiovascular events associated with decrements in 
peripheral vascular function is continuous.  
Besides claudication, commonly used criteria for 
diagnosing peripheral arterial disease include an 
ankle/brachial index (ABI); <0.9 determined by the ratio 
of systolic BP at the posterior tibial artery at the level of 
the ankle divided by the brachial artery pressure; flow 
velocity deficits measured by Doppler; the absence of 
posterior tibial or dorsalis pedis pulses; and intermittent 
claudication. In studies in which at least two of these 
criteria were used, prevalence rates ranged from 6% to 
20%. Asymptomatic patients have survival rates that are 
not significantly different from those with symptoms, 
suggesting that claudication is not a reliable marker for 
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severity of disease. Thus, when peripheral artery disease 
is considered a problem only in the presence of 
claudication, the majority of the population at risk is 
discounted. The ABI and measurements with a hand-
held Doppler in an outpatient setting can reliably 
diagnose the majority of peripheral artery disease.
30
 
Risk Factors 
Smoking is the most consistently associated risk factor, 
and prevalence rates in nonsmokers are less than half 
that of smokers. Other risk factors include glucose 
intolerance, increased body mass index, elevated blood 
pressure, and elevated fibrinogen. The association 
between peripheral artery disease and lipids is less 
definitive. Except for the importance of smoking, the 
risk factor profile common in peripheral artery disease 
shares features with the metabolic syndrome, glucose 
intolerance with low HDL cholesterol and often normal 
levels of LDL cholesterol, with a large fraction of the 
LDL cholesterol in a dense, more atherogenic form.
 
An 
association with the metabolic syndrome in persons 
whose total and LDL cholesterol levels are normal may 
explain the inconsistent associations for lipids.  
The degree of overlap in risk factors between peripheral 
artery disease and other major atherosclerotic CVD 
varies considerably by population and the diagnostic 
criteria applied. In the Cardiovascular Health Study 
peripheral artery disease was associated with increased 
carotid wall thickness, abnormal cardiac wall motion, 
and major electrocardiographic abnormalities. The 
Atherosclerosis Risk in Communities Study found 
peripheral artery disease to be the most important 
predictor of carotid thickness. Similarly, 25% of women 
with a history of coronary disease or stroke had 
peripheral artery disease, compared with an 11% 
prevalence of peripheral artery disease in women 
without this history. Typically, the more detailed the 
assessment of the arterial tree, the greater the 
concordance between peripheral arterial, coronary, and 
cerebrovascular diseases. 
Peripheral artery disease itself is a strong risk factor for 
other cardiovascular events and mortality. There is a 
threefold to fourfold increase in relative risk for all-
cause mortality associated with peripheral arterial 
disease that does not differ by gender. The relative risk 
for cardiovascular death is between 4 and 6, and the 
relative risk for CHD death is between 4 and 7. 
Moreover, adjustment for risk factors and exclusion of 
persons with a history of other CVD at baseline does not 
attenuate these risks, suggesting that once manifested, 
the disease itself is an independent predictor of 
survival.
31
 
Treatment 
Smoking cessation is essential for any patient still 
smoking when peripheral artery disease is recognized. 
Antiplatelet therapy may be effective in reducing 
adverse outcomes. Surgery is indicated for severe 
disease and may reduce direct sequelae of poor 
peripheral circulation, but, just as for coronary disease, a 
comprehensive program of atherosclerotic risk reduction 
and exercise is necessary to reduce risk of other 
cardiovascular events. Despite ambiguity about the 
association between lipids and peripheral artery disease, 
lipid-lowering therapy is likely to be protective.
32
  
Women and Coronary Artery Disease 
In the United States, CHD is the leading cause of death 
in both men and women, claiming more lives than 
cancer, accidents, and diabetes combined.
 
Although 
breast cancer may be more feared, age-adjusted death 
rates from CVD in women are 4 times higher in white 
women and 6 times higher in black women than the 
death rates for breast cancer.  
The 2010 ACCF/AHA report on assessment of 
cardiovascular risk in asymptomatic adults includes the 
recommendation that for all adult women and men, 
global risk scoring should be performed and a family 
history of cardiovascular disease should be obtained for 
cardiovascular risk assessment.
33
 
Compared with men, LDL cholesterol is lower and HDL 
cholesterol is higher in women before menopause. 
Although women have lower rates of hypertension and 
cigarette smoking than men, rates for obesity and 
diabetes mellitus are higher. Diabetes mellitus is a 
particularly serious risk factor in women, tripling the 
risk of cardiovascular death and causing diabetic women 
to have the same frequency of CVD as diabetic men.
 
HDL cholesterol and triglyceride levels are more 
predictive of CVD in women than in men.
 
Women have 
been noted to have similar or slightly higher prevalence 
of stable angina as compared to men.
 
 
It is now known that women tend to present more 
commonly with unstable angina as compared to men, 
the reverse of which is true for MI. However, when 
women do present with MI, they are more likely to have 
Q wave rather than non-Q wave.
 
Mortality rates of MI 
and CABG are about 50% higher in women, mostly 
related to older age of onset. Lipid lowering has shown 
similar efficacy in women and men in the angiographic 
progression and event trials. Cardio protective agents, 
including aspirin, beta-blockers, and ACE inhibitors, 
appear to have similar efficacy in men and women.  
Hormone therapy is no longer recommended to prevent 
coronary events in postmenopausal women with or 
without established CHD. Although hormone therapy 
improves LDL and HDL cholesterol levels, it also 
increases coagulation and inflammation (as measured by 
C-reactive protein [CRP]) and decreases LDL particle 
size. Treatment rates for risk factors in women tend to 
be even lower than in men, as are rates for coronary 
angiography and coronary artery revascularization 
following presentation with chest pain. 
Women who may have had radiotherapy through the 
mid-1980s to treat breast cancer are also at an increased 
risk of mortality from cardiovascular disease. The 
concern is even greater if the woman was treated for a 
left-sided breast cancer with contemporary tangential 
breast or chest wall radiotherapy.
 
 
Finally, it must be emphasized that while the guidelines 
detailed above represent best practice, their formulation 
is often a blend of science and art. Therefore, guideline 
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interpretation should always occur alongside good 
clinical judgment
34
.  
DISCUSSION 
CVD in women will continue to be a public health 
priority as significant numbers of aging women are at 
increased risk for morbidity and mortality related to 
CVD. Healthcare systems need to begin to shift 
paradigms to emphasize healthy lifestyles for young 
women. This approach will help prevent development of 
risk factors and minimize the need to manage them at a 
later time. Healthcare providers need to be sensitive to 
gender differences in presentation, prognosis, and 
responsiveness to treatment of CVD. Scientists are 
encouraged to continue to examine potential differences 
between men and women in the pathophysiology and 
clinical outcomes of CVD. More research in minority 
women is of particular importance, given the high level 
of risk factors and mortality rates in this population. 
Health educators will play a pivotal role in 
communicating and translating scientific developments 
about women and heart disease. Public policy makers 
should take the lead in ensuring that women of diverse 
backgrounds and circumstance have equal access to 
care. It is only through a multifaceted approach that 
cardiovascular science and medicine can be advanced 
for the betterment of all.  
CONCLUSION 
Evidence suggests that CVD can be prevented in 
women. Clinical recommendations are provided to assist 
healthcare providers and the public in efforts to avoid an 
initial or recurrent cardiovascular event. Our systematic 
search of the literature shows that several prevention 
strategies are likely to have substantially greater benefit 
than risk and that some interventions are likely to be 
associated with greater risk than benefit. It is important 
that the public be appropriately informed about 
potentially lifesaving preventive therapies and take 
action to lower their risk. On the basis of our review of 
the scientific evidence, it appears the risk of no action is 
far greater than that of applying knowledge to prevent 
CVD. Moreover, elderly women, especially those over 
80, in whom CVD is common. These results suggest 
that identiﬁcation of hypertension in women should 
dictate additional CAD risk assessment and risk factor 
management.
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